Q1 EPS Forecast for USANA Health Sciences Lowered by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti Csr cut their Q1 2025 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research report issued on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings of $0.71 per share for the quarter, down from their previous forecast of $0.77. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.71 EPS, FY2025 earnings at $2.75 EPS, Q2 2026 earnings at $0.81 EPS and Q4 2026 earnings at $0.92 EPS.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million.

USNA has been the topic of a number of other reports. DA Davidson boosted their price target on USANA Health Sciences from $35.00 to $38.00 and gave the company a “neutral” rating in a report on Thursday, January 2nd. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.

USANA Health Sciences Trading Up 3.8 %

Shares of NYSE USNA opened at $33.17 on Thursday. The company has a fifty day moving average price of $33.62 and a 200 day moving average price of $36.61. The firm has a market cap of $632.26 million, a PE ratio of 11.72, a PEG ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 1-year low of $30.13 and a 1-year high of $50.32.

Institutional Investors Weigh In On USANA Health Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in USNA. Creative Planning acquired a new stake in shares of USANA Health Sciences in the third quarter valued at about $394,000. Allspring Global Investments Holdings LLC raised its stake in shares of USANA Health Sciences by 14,068.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock worth $1,472,000 after purchasing an additional 38,547 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of USANA Health Sciences by 13.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock worth $4,702,000 after purchasing an additional 14,756 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of USANA Health Sciences by 44.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company’s stock valued at $336,000 after buying an additional 2,713 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares in the last quarter. 54.25% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.